A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer

• Published in: American journal of clinical oncology Vol. 41; no. 8; p. 772
• Main Authors: Cardin, Dana B, Thota, Ramya, Goff, Laura W, Berlin, Jordan D, Jones, Clyde M, Ayers, Gregory D, Whisenant, Jennifer G, Chan, Emily
• Format: Journal Article
• Language: English
• Published: United States 01.08.2018
• Subjects: Adult; Aged; Carcinoma, Pancreatic Ductal - drug therapy; Carcinoma, Pancreatic Ductal - secondary; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Prognosis; Salvage Therapy; Survival Rate; Triazoles - therapeutic use
• ISSN: 1537-453X
• DOI: 10.1097/COC.0000000000000377

Heat shock protein 90 regulates multiple signaling proteins involved in key pathways of pancreatic cancer pathogenesis. Ganetespib binds to heat shock protein 90 and interferes with its binding to client proteins thus leading to inactivation and degradation of the signaling proteins that promote cancer progression. This phase II study was designed to evaluate the efficacy of ganetespib in patients with refractory metastatic pancreatic cancer (rMPC). Patients with rMPC received 175 mg/m ganetespib intravenously once weekly for 3 weeks in 4-week cycles. Primary endpoint was disease control rate at 8 weeks, with a goal of 70%. Secondary endpoints were progression-free survival, overall survival, and safety. Simon's 2-stage design was used to assess futility and efficacy. Ganetespib was considered inactive if ≤8 patients among the first 15 treated had disease control after 8 weeks of treatment. Fourteen patients were treated on study. Grade 3 treatment-related toxicities were diarrhea, abdominal pain, fatigue, nausea, vomiting, and hyponatremia. Disease control rate at 8 weeks was 28.6%, and median progression-free survival and overall survival were 1.58 months and 4.57 months, respectively. Early stopping rules for lack of clinical efficacy led to study closure. Single-agent ganetespib was tolerable with only modest disease control in rMPC. This disease is resistant to chemotherapy, and given the emerging data in lung and rectal cancers, as well as in pancreatic cancer cell lines, suggesting improved activity of ganetespib in combination with cytotoxic agents, studies combining this agent with chemotherapy in rMPC are more likely to yield success.